Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2b vs Interferon Alfa in Essential Thrombocythemia
NCT05395507Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in essential thrombocythemia (ET), sponsored by Institute of Hematology and Blood Diseases Hospital. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT05395507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395507.